The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Estrogen plus progestin (E+P) and breast cancer incidence and mortality.
Rowan T. Chlebowski
Consultant or Advisory Role - AstraZeneca; Novartis
Honoraria - AstraZeneca; Novartis
Research Funding - Amgen
Garnet L Anderson
No relevant relationships to disclose
Lewis H Kuller
No relevant relationships to disclose
Aaron K Aragaki
No relevant relationships to disclose
JoAnn E Manson
No relevant relationships to disclose
Marcia L Stefanick
No relevant relationships to disclose
Karen Johnson
No relevant relationships to disclose
Margery Gass
Consultant or Advisory Role - Proctor and Gamble; Wyeth
Research Funding - Proctor and Gamble; Wyeth
Dorothy S Lane
No relevant relationships to disclose
Judith Ockene
No relevant relationships to disclose
Gloria Sarto
No relevant relationships to disclose
Jean Wactawski-Wende
No relevant relationships to disclose
Aleksandar Rajkovic
No relevant relationships to disclose
Ross L Prentice
No relevant relationships to disclose